Goldman Sachs Asset Management completed the acquisition of a majority stake in Norgine from Stein Family for $1.9bn.

Goldman Sachs Asset Management completed the acquisition of a majority stake in Norgine, a European specialty pharmaceutical company, from Stein Family for $1.9bn. "I am delighted to announce this transformative investment by Goldman Sachs Asset Management which ensures that Norgine can accelerate its growth plans and develop and launch further innovative medicines for the benefit of patients. Norgine has been delivering on this crucial mission for over a century. With Goldman Sachs Asset Management’s support, Chris and the entire Norgine team will be able to expand upon this proud heritage. I am particularly pleased that, in partnership with Goldman Sachs Asset Management, my family will be able to continue its long association with the Company and I look forward to supporting Norgine in this exciting next phase of development," Peter Stein, Norgine Chairman.